“The application of biomedical image in cardiology allows us to investigate innovative technologies to address the problems of current therapies and improve their future effectiveness.”

-project Cenit for the Ministry of science and innovation CVREMOD: convergence of medical technologies for the integrated management of the Cardiovascular remodelling, today presented his initiative and evolution in first year since its inception underway within the framework of the Congress of the Spanish society of Cardiology held in Valencia

-Congressdedicated to the study of cardiovascular disease, has gathered to the exponents in the scope of the study and treatment of these pathologies

Valencia, October 2010- the emergence and development of new technologies has led to a qualitative leap in the performance of biomedical images and their direct transfer on the improvement of cardiovascular Diagnostics. Although the current clinical practice related to cardiovascular disease has at its disposal a wide range of interventionist and medical treatments, there are still many questions to answer both basic knowledge and its implementation in actual clinical practice, where therapies are optimized for each patient. According to Dr. José Ángel Cabrera, Chief of the service of Cardiology Hospital Chiron Madrid, advances in biomedical image are allowing certain diseases early diagnosis, to a greater precision. These allow us to evaluate early and objectively the changes individually for each patient for treatment, putting a series of new tools, along with the usual clinical methodology available to health professionals, will enhance the effectiveness of diagnosis and treatment focused on the individual patient ”

CVREMOD aims at the assessment of the mechanisms of the remodeled cardiovascular with the highest mortality, researching innovative and integrated technologies to address the existing problems in current therapies and improve its effectiveness and suitability for each patient, addressing comprehensively in the different phases of the cycle of health care. The current vision of health systems should not be focusing on therapeutic acts or medical diagnoses isolated, but addressing the patient’s life or a particular clinical condition of integrative and comprehensive manner. In CVREMOD adopted a comprehensive vision to treat all stages of the cycle of health, from diagnosis to treatment, based on the understanding of the pathophysiology combined with efficient strategies for monitoring and prevention ”, said Dr. Marta Sitges, Coordinator of cardiac image of the Hospital Clínic of Barcelona.

Dr. Roberto Sanz, engineer of research biomedical of the Group of quantification of Chiron Valencia Hospital, has commented on the evolution and development of this ambitious project stressing the close collaboration between the different working groups with the realization of earlier versions and prototypes of population-based cardiac atlas, new textile tools of signal acquisition and the development and implementation of new algorithms which will result in the simulation tool that will be validated in the third year by the clinical setting involved in the project ”

CVREMOD project has been designed to provide an improved response coordinating and consolidating the necessary critical mass within Spanish ecosystem of technology, so that support to the Spanish industry of medical products and attract to Spain investment r & d of multinational companies in the sector. In this way, will be achieved make the competitive r & d worldwide, resolutely committed to leadership and visibility of Spain in this area.

The CVREMOD project aims at:

1. Validate computational physiological models by understanding the basic mechanisms involved in the cardiovascular remodeling through animal experimentation

2. Enable pervasive monitoring of multidimensional patient physiological information and integrate it in hospital information systems

3. View the mechanisms of cardiovascular remodeled through advanced image protocols, new contrast media and techniques of image posproceso

4. Extend the use of computational models to help in the advanced planning of interventions minimally invasive

5. Transfer the knowledge generated to six clinical stages of clinical evaluation and demonstration

the research being carried out in two distinct groups. On the one hand, the axis clinical Experimental, where there are specific evaluation scenarios, including animal experiments and clinical validation; and, on the other hand, the technological axis, where they investigate and develop new technologies in key areas defined beforehand by the experimental clinical axis.

Participating private entities are: AB Biotics industrial productions of Microbiotas, Atos Origin, Quirón hospital, Philips healthcare, Plastiasite, RGB Medical Devices, Sorin Group Spain, Transmural Biotech hospital, UDIAT Centre diagnosis.

The research organizations involved are: Association Center for cooperative research in biomaterials (CIC biomaGUNE), technological centre Cetemmsa, Fundació Clínic per a the biomedical research of the Hospital Clínic i Provincial de Barcelona, Fundació Privada ASCAMM, Foundation Doctor Peset, Institute of computer applications (IAC3)Institut d ’ Investigacions Biomèdiques August Pi i Sunyer, Universidad Autónoma de Madrid, Universitat Pompeu Fabra and Universidad de Valladolid.